- Conditions
- Depression
- Interventions
- Placebo, identified as placebo to participants, Celexa or other antidepressant as clinically indicated, Placebo, identifed to participants as "Active medication"
- Other · Drug
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 49–72
of 79
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Schizophrenia
- Interventions
- CAD-9303, Placebos
- Drug
- Lead sponsor
- Cadent Therapeutics
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 103 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 2
- States / cities
- Long Beach, California • Marlton, New Jersey
- Conditions
- Healthy Adult Subjects, Sickle Cell Disease
- Interventions
- FTX-6058/placebo oral capsule(s), FTX-6058 - Two Dosing Periods, FTX-6058 / Midazolam Syrup
- Drug
- Lead sponsor
- Fulcrum Therapeutics
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 109 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2022
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia • Overland Park, Kansas
- Conditions
- Sickle Cell Disease, Sickle-Beta Zero Thalassemia
- Interventions
- SCD-101
- Drug
- Lead sponsor
- Invenux, LLC
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2023
- U.S. locations
- 1
- States / cities
- Brooklyn, New York
- Conditions
- Chronic Obstructive Pulmonary Disease, COPD
- Interventions
- QBW251, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 92 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 14
- States / cities
- Birmingham, Alabama • Fullerton, California • Waterbury, Connecticut + 11 more
- Conditions
- Non-small Cell Lung Cancer (NSCLC)
- Interventions
- Taletrectinib, Placebo
- Drug
- Lead sponsor
- Nuvation Bio Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2033
- U.S. locations
- 12
- States / cities
- Los Angeles, California • Orange, California • Washington D.C., District of Columbia + 9 more
- Conditions
- Iron Deficiency Anemia Treatment, Iron Deficiency, Iron Deficiency (Without Anemia)
- Interventions
- FeoSol Original Iron Supplement Tablets, 21st Century Gelatin Capsules
- Dietary Supplement
- Lead sponsor
- Purdue University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 240 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- West Lafayette, Indiana
- Conditions
- Atopic Asthma
- Interventions
- Oral Silymarin, Oral Silymarin, maintenance dose, Placebo
- Drug
- Lead sponsor
- Vanderbilt University
- Other
- Eligibility
- 18 Years to 75 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Carcinoma, Hepatocellular
- Interventions
- Lenvatinib, Pembrolizumab, Oral Placebo, IV Placebo, TACE
- Drug · Biological · Procedure
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 480 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 27
- States / cities
- Tucson, Arizona • La Jolla, California • Los Angeles, California + 22 more
- Conditions
- ADPKD (Autosomal Dominant Polycystic Kidney Disease)
- Interventions
- Bempedoic Acid 180 MG Oral Tablet, Placebo Capsule(s)
- Drug
- Lead sponsor
- Kenneth Hallows
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 3
- States / cities
- Baltimore, Maryland • Boston, Massachusetts • Burlington, Vermont
- Conditions
- Healthy Volunteers
- Interventions
- Rhodiola rosea (low dose), Rhodiola rosea (high dose), Placebo capsules
- Dietary Supplement
- Lead sponsor
- Jacksonville State University
- Other
- Eligibility
- 18 Weeks to 40 Weeks
- Enrollment
- 27 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Jacksonville, Alabama
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Canagliflozin 100 mg, Canagliflozin 300 mg, Antihyperglycemic agent(s), Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 55 Years to 80 Years
- Enrollment
- 716 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 34
- States / cities
- Glendale, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 31 more
- Conditions
- Renal Insufficiency, Chronic, Hyperkalemia
- Interventions
- Sodium Zirconium Cyclosilicate (SZC), Placebo, Lisinopril, Valsartan, Irbesartan
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 1,112 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 42
- States / cities
- Surprise, Arizona • Tucson, Arizona • Canyon Country, California + 36 more
- Conditions
- Healthy Adult Subjects
- Interventions
- MBX-400, Placebo
- Drug · Other
- Lead sponsor
- Microbiotix, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Hackensack, New Jersey
- Conditions
- Neurobehavioral Disinhibition
- Interventions
- Placebo, AVP-786-28, AVP-786-42.63
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 168 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 54
- States / cities
- Tuscaloosa, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 45 more
- Conditions
- Migraine Headache
- Interventions
- Propranolol or nadolol, Placebo control, Behavioral Migraine Management (BMM), Optimal Acute Therapy
- Drug · Behavioral
- Lead sponsor
- Ohio University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 232 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2005
- U.S. locations
- 2
- States / cities
- Athens, Ohio • Westerville, Ohio
- Conditions
- Major Depressive Disorder
- Interventions
- BTRX-246040 oral capsule(s), Placebo oral capsule(s)
- Drug
- Lead sponsor
- BlackThorn Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 104 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 8
- States / cities
- Cerritos, California • Garden Grove, California • Jacksonville, Florida + 5 more
- Conditions
- Alzheimer's Disease
- Interventions
- Placebo Capsule(s) Once a Day by Mouth, Nilotinib Capsule(s) Once a Day by Mouth
- Drug
- Lead sponsor
- Georgetown University
- Other
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Iron Deficiency (ID), Pregnancy
- Interventions
- Lactiplantibacillus plantarum 299v, Placebo Capsule(s)
- Dietary Supplement · Other
- Lead sponsor
- University of Illinois at Chicago
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 250 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Insulin Resistance, Mild Cognitive Impairment, Cognitive Decline, Neurodegenerative Disorders
- Interventions
- Sabroxy®, Placebo
- Dietary Supplement · Other
- Lead sponsor
- SF Research Institute, Inc.
- Network
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 140 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Drug Safety
- Interventions
- Placebo, VIA-3196
- Drug
- Lead sponsor
- Madrigal Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012
- U.S. locations
- 1
- States / cities
- Fargo, North Dakota
- Conditions
- Rheumatoid Arthritis
- Interventions
- CP-690,550, Methotrexate, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 694 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 59
- States / cities
- Huntsville, Alabama • Gilbert, Arizona • Peoria, Arizona + 48 more
- Conditions
- Epilepsy
- Interventions
- AED treatment plus placebo, Keishibukuryogan
- Drug
- Lead sponsor
- Timothy Welty, PharmD
- Other
- Eligibility
- 21 Years to 45 Years · Female only
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Kansas City, Kansas
- Conditions
- Hypertriglyceridemia, Cardiovascular Disease
- Interventions
- Olive oil, 4g, omega-3-carboxylic acids, 2g, omega-3-carboxylic acids, 4g
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 646 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 89
- States / cities
- Muscle Shoals, Alabama • Chandler, Arizona • Phoenix, Arizona + 78 more